HUE052210T2 - Egy TLR7 agonista trifluoracetát sója és annak B kristályos formája, elõállítási eljárások és alkalmazások - Google Patents
Egy TLR7 agonista trifluoracetát sója és annak B kristályos formája, elõállítási eljárások és alkalmazásokInfo
- Publication number
- HUE052210T2 HUE052210T2 HUE17747007A HUE17747007A HUE052210T2 HU E052210 T2 HUE052210 T2 HU E052210T2 HU E17747007 A HUE17747007 A HU E17747007A HU E17747007 A HUE17747007 A HU E17747007A HU E052210 T2 HUE052210 T2 HU E052210T2
- Authority
- HU
- Hungary
- Prior art keywords
- crystalline form
- preparation methods
- trifluoroacetate salt
- tlr7 agonist
- tlr7
- Prior art date
Links
- 229940124615 TLR 7 agonist Drugs 0.000 title 1
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Physics & Mathematics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Physics & Mathematics (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610081899.3A CN107043377A (zh) | 2016-02-05 | 2016-02-05 | 一种tlr7激动剂的三氟乙酸盐、晶型b及其制备方法、药物组合物和用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE052210T2 true HUE052210T2 (hu) | 2021-04-28 |
Family
ID=59500539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE17747007A HUE052210T2 (hu) | 2016-02-05 | 2017-02-04 | Egy TLR7 agonista trifluoracetát sója és annak B kristályos formája, elõállítási eljárások és alkalmazások |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US10683296B2 (enExample) |
| EP (1) | EP3412674B1 (enExample) |
| JP (1) | JP6877450B2 (enExample) |
| KR (1) | KR102393281B1 (enExample) |
| CN (2) | CN107043377A (enExample) |
| AR (1) | AR107550A1 (enExample) |
| AU (1) | AU2017214135B2 (enExample) |
| CA (1) | CA3013521C (enExample) |
| CL (1) | CL2018002101A1 (enExample) |
| DK (1) | DK3412674T3 (enExample) |
| EA (1) | EA037048B1 (enExample) |
| ES (1) | ES2834304T3 (enExample) |
| HU (1) | HUE052210T2 (enExample) |
| IL (1) | IL260981B (enExample) |
| MX (1) | MX374300B (enExample) |
| MY (1) | MY198137A (enExample) |
| NZ (1) | NZ745023A (enExample) |
| PH (1) | PH12018501641B1 (enExample) |
| SG (1) | SG11201806688QA (enExample) |
| TW (1) | TWI778952B (enExample) |
| UA (1) | UA121276C2 (enExample) |
| WO (1) | WO2017133687A1 (enExample) |
| ZA (1) | ZA201805240B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107043380A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途 |
| CN107043378A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体 |
| EP3414239A2 (en) | 2016-02-05 | 2018-12-19 | Denali Therapeutics Inc. | Inhibitors of receptor-interacting protein kinase 1 |
| JP7385602B2 (ja) * | 2018-05-25 | 2023-11-22 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | 肺癌を治療するためのｔｌｒ７アゴニストおよびその医薬の組み合わせ |
| JP7287708B2 (ja) | 2019-02-08 | 2023-06-06 | プロジェニア インコーポレイテッド | Ｔｏｌｌ－ｌｉｋｅ受容体７または８アゴニストとコレステロールの結合体およびその用途 |
| CA3170551A1 (en) | 2020-03-02 | 2021-09-10 | Yong Taik Lim | Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof |
| WO2022031011A1 (ko) | 2020-08-04 | 2022-02-10 | 성균관대학교산학협력단 | 동력학적으로 작용하는 아주번트 앙상블 |
| EP4194010A4 (en) | 2020-08-04 | 2025-03-26 | Progeneer Inc. | Conjugate of a functional drug and a toll-like receptor 7 or 8 agonist with a temporarily inactivated drug site, and use thereof |
| EP4194006A4 (en) | 2020-08-04 | 2024-12-04 | Progeneer Inc. | mRNA VACCINE WITH AN ADJUVANT CAPABLE OF KINETIC CONTROL |
| EP4463229A1 (en) | 2022-01-12 | 2024-11-20 | Denali Therapeutics Inc. | Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide |
| CN119431359A (zh) * | 2023-07-28 | 2025-02-14 | 苏州申拓医药科技有限公司 | 一种tlr7/8激动剂的可药用盐、晶型及其制备方法、药物组合物和用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3376479B2 (ja) * | 1991-08-12 | 2003-02-10 | 武田薬品工業株式会社 | 縮合ピリミジン誘導体、その製造法および用途 |
| BRPI0923305B1 (pt) | 2008-12-09 | 2019-01-22 | Gilead Sciences Inc | moduladores de receptores toll-like, seu uso e composição farmacêutica que os compreende |
| CA2826295C (en) * | 2011-02-04 | 2020-10-20 | Duquesne University Of The Holy Spirit | Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient |
| WO2013103967A1 (en) * | 2012-01-05 | 2013-07-11 | Northeastern University | Allosteric modulators of cb1 cannabinoid receptors |
| PT2906563T (pt) * | 2012-10-10 | 2018-05-23 | Janssen Sciences Ireland Uc | Derivados de pirrolo[3,2-d]pirimidina para o tratamento de infeções virais e outras doenças |
| EP2922550B1 (en) * | 2012-11-20 | 2017-04-19 | Glaxosmithkline LLC | Novel compounds |
| PT3137470T (pt) * | 2014-05-01 | 2021-06-24 | Novartis Ag | Compostos e composições como agonistas do recetor tipo toll 7 |
| KR20160144399A (ko) * | 2014-05-01 | 2016-12-16 | 노파르티스 아게 | 톨-유사 수용체 7 효능제로서의 화합물 및 조성물 |
| CN105367576A (zh) * | 2014-08-15 | 2016-03-02 | 正大天晴药业集团股份有限公司 | 作为tlr7激动剂的吡咯并嘧啶化合物 |
| UA117634C2 (uk) * | 2014-08-15 | 2018-08-27 | Чиа Тай Тяньцін Фармасьютикал Ґруп Ко., Лтд. | Піролопіримідинові сполуки, що використовуються як агоніст tlr7 |
| CN105732635A (zh) * | 2014-12-29 | 2016-07-06 | 南京明德新药研发股份有限公司 | 一类Toll样受体7激动剂 |
-
2016
- 2016-02-05 CN CN201610081899.3A patent/CN107043377A/zh active Pending
-
2017
- 2017-02-03 TW TW106103697A patent/TWI778952B/zh active
- 2017-02-04 EA EA201891772A patent/EA037048B1/ru not_active IP Right Cessation
- 2017-02-04 WO PCT/CN2017/072894 patent/WO2017133687A1/zh not_active Ceased
- 2017-02-04 HU HUE17747007A patent/HUE052210T2/hu unknown
- 2017-02-04 EP EP17747007.7A patent/EP3412674B1/en active Active
- 2017-02-04 MX MX2018009503A patent/MX374300B/es active IP Right Grant
- 2017-02-04 US US16/075,303 patent/US10683296B2/en active Active
- 2017-02-04 KR KR1020187024629A patent/KR102393281B1/ko active Active
- 2017-02-04 MY MYPI2018702700A patent/MY198137A/en unknown
- 2017-02-04 DK DK17747007.7T patent/DK3412674T3/da active
- 2017-02-04 JP JP2018540797A patent/JP6877450B2/ja active Active
- 2017-02-04 SG SG11201806688QA patent/SG11201806688QA/en unknown
- 2017-02-04 UA UAA201809128A patent/UA121276C2/uk unknown
- 2017-02-04 NZ NZ745023A patent/NZ745023A/en unknown
- 2017-02-04 AU AU2017214135A patent/AU2017214135B2/en active Active
- 2017-02-04 ES ES17747007T patent/ES2834304T3/es active Active
- 2017-02-04 CA CA3013521A patent/CA3013521C/en active Active
- 2017-02-04 CN CN201780009751.1A patent/CN108602833B/zh active Active
- 2017-02-06 AR ARP170100299A patent/AR107550A1/es not_active Application Discontinuation
-
2018
- 2018-08-02 PH PH12018501641A patent/PH12018501641B1/en unknown
- 2018-08-03 CL CL2018002101A patent/CL2018002101A1/es unknown
- 2018-08-03 ZA ZA2018/05240A patent/ZA201805240B/en unknown
- 2018-08-05 IL IL260981A patent/IL260981B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE052210T2 (hu) | Egy TLR7 agonista trifluoracetát sója és annak B kristályos formája, elõállítási eljárások és alkalmazások | |
| IL260968B (en) | Type a crystal structure of trl7 agonist, methods of preparation and its uses | |
| IL253186B (en) | A new crystalline form of a benzaimidazole derivative and a method for its preparation | |
| PT3133068T (pt) | Derivados de amida e sais farmacêuticos destes, método de preparação destes e aplicação medicinal destes | |
| IL255738A (en) | A new crystalline form of lenbatinib mesylate and a process for its preparation | |
| IL260965B (en) | The malate salt as an agonist of tlr7, its c, d and e crystal structures, preparation methods and uses of the malate salt and the crystal structures | |
| LT3470400T (lt) | Ozanimodo ir ozanimodo hidrochlorido kristalinės formos ir jų gamybos būdo procesai | |
| PT3580219T (pt) | Processo para a preparação de remimazolam e formas de estado sólido de sais de remimazolam | |
| SG11201608372PA (en) | Irinotecan hydrochloride composite phospholipid composition, preparation method and use thereof | |
| SG11201609405VA (en) | Carotenoid derivative, pharmaceutically acceptable salt thereof, and pharmaceutically acceptable ester or amide thereof | |
| EP3235851A4 (en) | Nylon salt and preparation method therefor | |
| IL254530A0 (en) | Preparation method of crystalline form a of pci-32765 | |
| ZA201704743B (en) | Mangiferin-6-o-berberine salt and preparation method and use thereof | |
| PL3327012T3 (pl) | Krystaliczne postacie bilastyny i sposoby ich wytwarzania | |
| PL3377049T3 (pl) | Krystaliczne formy soli tapentadolu i sposób ich wytwarzania | |
| EP3302099A4 (en) | Enhanced salt compositions and methods of preparation thereof | |
| ME03727B (me) | Zamjena za so i njena primena | |
| SG11201911936YA (en) | Substituted quinolinycyclohexylpropanamide compounds and improved methods for their preparation | |
| GB2546513B (en) | Process of preparing active pharmaceutical ingredient salts | |
| GB201610867D0 (en) | Crystalline forms of a therapeutic compound and processes for their preparation | |
| IL254597A0 (en) | Crystalline form of ahu377, method for its preparation and use | |
| IL246835A0 (en) | Improved process for the preparation of trazodone and its hydrochloride salt | |
| PT3140287T (pt) | Novo sal de ivabradina e um processo para a sua preparação | |
| GB201400270D0 (en) | Injectable active ingredient release compositions and methods for their production and use |